Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

BACKGROUND: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but l...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Moehler, Markus, Gepfner-Tuma, Irina, Maderer, Annett, Thuss-Patience, Peter C., Ruessel, Joern, Hegewisch-Becker, Susanna, Wilke, Hansjochen, Al-Batran, Salah-Eddin, Rafiyan, Mohammad-Reza, Weißinger, Florian, Schmoll, Hans-Joachim, Kullmann, Frank, von Weikersthal, Ludwig Fischer, Siveke, Jens T., Weusmann, Jens, Kanzler, Stephan, Schimanski, Carl Christoph, Otte, Melanie, Schollenberger, Lukas, Koenig, Jochem, Galle, Peter R.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006426/
https://ncbi.nlm.nih.gov/pubmed/27582078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2736-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker